Entrada Therapeutics, Inc.
TRDAHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Entrada Therapeutics, Inc. focuses on Biotechnology services and products. Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that. With a market capitalization of $274.5M, it sits in micro-cap territory. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Market Cap
$274.5M
Beta
-0.09
P/E (TTM)
—
P/E (Fwd)
-2.08
EPS (TTM)
$-4.00
EPS (Fwd)
$-3.41
ROE
-48.3%
ROA
-26.8%
Cash
$254.9M
Total Debt
$49.8M
Free CF
-$75.4M
52W Change
-13.1%
Annual Financials
Cash vs Debt
Entrada Therapeutics, Inc. holds $254.9M in cash against $49.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$75.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -48.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
TRDA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Entrada Therapeutics, Inc. and its sector.